Diagnostic and therapeutic challenges of myasthenia gravis: a report of 2 cases

• Autorzy: Poleszek J. , Szabat P. , Jasielski P. , Szabat M. , Petit V. , Fidor A. , Rejdak K.
• Języki publikacji: EN

Abstrakty

EN

Słowa kluczowe

EN

myasthenia gravis; autoimmune disease; neuromuscular junction; plasmapheresis; immunosuppressive treatment; human disease; diagnostics; treatment

• Wydawca: -
• Czasopismo: World News of Natural Sciences
• Rocznik: 2020
• Tom: 31
• Opis fizyczny: p.138-145,fig.,ref.

Twórcy

autor

Poleszek J.

• Department of Neurology, Medical University of Lublin, Lublin, Poland

autor

Szabat P.

• Department of Neurology, Medical University of Lublin, Lublin, Poland

autor

Jasielski P.

• Department of Neurology, Medical University of Lublin, Lublin, Poland

autor

Szabat M.

• Department of Neurology, Medical University of Lublin, Lublin, Poland

autor

Petit V.

• Department of Neurology, Medical University of Lublin, Lublin, Poland

autor

Fidor A.

• Department of Neurology, Medical University of Lublin, Lublin, Poland

autor

Rejdak K.

• Department of Neurology, Medical University of Lublin, Lublin, Poland

Bibliografia

• [1] Evoli. Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol. 30(5) (2017) 464-470
• [2] M. Padilla Parrado, J.M. Morales Puebla, M.A. Díaz Sastre, et al. Respiratory stridency by larynx paralysis. Anusual beginning of miastenia. An Otorrinolaringol Ibero Am. 33(3) (2006) 307-315
• [3] J.W. Fairley, M. Hughes. Acute stridor due to bilateral vocal fold paralysis as a presenting sign of myasthenia gravis. J Laryngol Otol. 106(8) (1992) 737-748
• [4] Emeryk-Szajewska, M.H. Strugalska-Cynowska. Clinical picture of myasthenia gravis: diagnostic difficulties. Pol Przegl Neurol. 2(3) (2006) 145-149
• [5] M.H. Strugalska-Cynowska. Myasthenia gravis and Lambert-Eaton myasthenic syndrome (clinical and immunological advances, signifity of autoantibodies for diagnosis and treatment). Pol Przegl Neurol. 15(1) (2019) 75-76
• [6] W. Hoch, J. McConville, S. Helms, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylocholine receptor antibodies. Natur Medicine 7 (2001) 365-368
• [7] H. Murai. Myasthenia gravis: past, present and future. Rinsho Shinkeigaku 54(12) (2014) 947-949
• [8] Węgrzyn, J. Andres, D. Tomasik. Myasthenic crisis. Case report. Anestezjol Intensyw Terap. 3 (2002) 194-196
• [9] Z. Rybicki. Intensywna terapia dorosłych. Novus Orbis. 1994, Gdańsk, Poland.
• [10] N.E. Gilhus. Myasthenia Gravis. N Engl J Med. 375(26) (2016) 2570-2581
• [11] K. Rejdak, S. Szklener, A. Korchut, et al. Cladribine in Myasthenia Gravis: A Pilot Open-Label Study. Eu J Neurol. 27(3) (2020) 586-589
• [12] Daga Ruiz, S.M. Fonseca, F.J. González de Molina, et al. Plasmapheresis and other extracorporeal filtration techniques in critical patients. Med Intensiva 41(3) (2017) 174-187
• [13] W. Köhler, C. Bucka, R. Klingel, et al. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. Journal of Clinical Apheresis 26(6) (2011) 347-355
• [14] I. Trikha, S. Singh, V. Goyal, et al. Comparative efficacy of low dose, daily versus alternative day plasma exchange in severe myasthenia gravis: A randomized trial. Journal of Neurology 254 (2007) 989-995
• [15] M.F. Yazdi, M. Baghianimoghadam, H. Nazmiyeh, et al. Response to plasmapheresis in myasthenia gravis patients: 22 cases report. Rom J Intern Med. 50(3) (2012) 245-247
• [16] A.J. Pinching, D.K. Peters. Remission of myasthenia gravis following plasma-exchange. Lancet 2 (1976) 1373-1376
• [17] P.C. Dau, J.M. Lindstrom, C.K. Cassel, et al. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med. 297(21) (1977) 1134-1140
• [18] R. Kumar, S.P. Birinder, S. Gupta, et al. Therapeutic plasma exchange in the treatment of myasthenia gravis. Indian J Crit Care Med. 19(1) (2015) 9-13
• [19] A. Mandawat, A. Mandawat, H.J. Kaminski, et al. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve. 43(4) (2011) 578-84
• [20] W. Szczeklik, K. Wawrzycka, A. Włudarczyk, Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 45(1) (2013) 7-13.
• [21] P. Gajdos, S. Chevret, K. Toyka. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 4 (2002) 2275.
• [22] P.C. Dau. Plasmapheresis in myasthenia gravis. Prog Clin Biol Res. 88 (1982) 265-285.
• [23] R.L. Rodnitzky, J.A. Goeken. Complications of plasma exchange in neurological patients. Arch Neurol. 39(6) (1982) 350-354
• [24] H. Ebadi, D. Barth, V. Bril. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve. 47(4) (2013) 510-514
• [25] A. Alipour-Faz, M. Shojaei, H. Peyvandi. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurol Belg. 117(1) (2017) 245-249.
• [26] S. Raif. Geha Charles A. Janeway and Fred S. Rosen: The discovery of gamma globulin therapy and primary immunodeficiency diseases at Boston Children's Hospital. Journal of Allergy and Clinical Immunology 116(4) (2005) 937-940
• [27] J. Rowin. Is plasmapheresis an effective treatment for myasthenia gravis? Americ Academ Of Neurolog. https://www.brainandlife.org/articles/is-plasmapheresis-an-effective-treatment-for-myasthenia-gravis/ [dostępny 01.06.2019]
• [28] P. Ortiz-Salas, A. Velez-Van-Meerbeke, C.A. Galvis-Gomez, et al. Human Immunoglobulin Versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis. J Clin Neuromuscul Dis. 18(1) (2016) 1-11
• [29] G. Barnett, D. Wilson, D. Barth, et al. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 84(1) (2013) 94-97